Global EMEA Point-Of-Care Diagnostics Market Size Study, by Product (Glucose Testing, Cancer Marker, Coagulation Testing, Infectious Disease), by End-use (Clinics, Home), and Regional Forecasts 2022-2032

Description

The Global EMEA Point-Of-Care Diagnostics Market is valued at approximately USD 13 billion in 2023 and is anticipated to grow at a steady CAGR of 6.20% during the forecast period 2024-2032.Point-of-care (POC) diagnostics are revolutionizing the medical landscape by providing rapid, on-site diagnostic results, empowering clinicians to make timely decisions, and improving patient outcomes. This technology spans various applications, including glucose monitoring, infectious disease detection, cancer marker identification, and coagulation testing. Its adoption is driven by the increasing demand for accessible, efficient healthcare solutions in clinics and home settings.

The market is propelled by the growing prevalence of chronic diseases, such as diabetes and cardiovascular disorders, which necessitate continuous monitoring and swift interventions. The proliferation of advanced technologies like microfluidics and biosensors has enhanced the accuracy and usability of POC devices, making them indispensable in both professional and home care environments. Furthermore, the increasing shift towards decentralized healthcare systems, supported by robust advancements in diagnostic capabilities, has amplified the demand for portable and user-friendly diagnostic tools.

However, challenges like high costs associated with advanced POC devices and limited awareness in developing regions could hamper growth. Nevertheless, the expanding focus on healthcare accessibility and the growing integration of IoT-enabled POC devices for real-time data tracking and remote monitoring are poised to create lucrative growth opportunities. The emergence of minimally invasive testing technologies is further enhancing patient compliance and driving innovation in the sector.

Regionally, Europe dominates the market, owing to its advanced healthcare infrastructure, high prevalence of chronic diseases, and favorable government initiatives supporting diagnostic advancements. The Middle East & Africa region is also witnessing significant growth, driven by increasing healthcare investments and improving access to medical technologies. Emerging markets in the EMEA region are adopting POC diagnostics to bridge healthcare gaps, particularly in rural and underserved areas.

Major market players included in this report are:

Abbott Laboratories
Siemens Healthineers AG
Roche Diagnostics
Danaher Corporation
QuidelOrtho Corporation
bioMerieux SA
Becton, Dickinson and Company
Sysmex Corporation
Hologic, Inc.
Thermo Fisher Scientific Inc.
Nova Biomedical
Bio-Rad Laboratories, Inc.
Chembio Diagnostics, Inc.
EKF Diagnostics Holdings plc
OraSure Technologies, Inc.

The detailed segments and sub-segments of the market are explained below:

By Product:

Glucose Testing
Cancer Marker
Coagulation Testing
Infectious Disease

By End-use:

Clinics
Home

By Region:

Europe:

UK
Germany
France
Spain
Italy
Rest of Europe

Middle East & Africa:

Saudi Arabia
South Africa
Rest of Middle East & Africa

Key Takeaways:

Comprehensive forecasts from 2022-2032, covering market segmentation and regional dynamics.
Strategic insights for stakeholders to leverage growth opportunities.
Analysis of the competitive landscape with key player strategies and innovations.
In-depth exploration of market drivers, challenges, and opportunities.

Chapter 1. Global EMEA Point-Of-Care Diagnostics Market Executive Summary

1.1. Global EMEA Point-Of-Care Diagnostics Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Product
- 1.3.2. By End Use
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global EMEA Point-Of-Care Diagnostics Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory Frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global EMEA Point-Of-Care Diagnostics Market Dynamics

3.1. Market Drivers
- 3.1.1. Growing Prevalence of Chronic Diseases
- 3.1.2. Advancements in Microfluidics and Biosensors
- 3.1.3. Shift Towards Decentralized Healthcare Systems
3.2. Market Challenges
- 3.2.1. High Costs Associated with Advanced POC Devices
- 3.2.2. Limited Awareness in Developing Regions
3.3. Market Opportunities
- 3.3.1. Integration of IoT-Enabled POC Devices
- 3.3.2. Emergence of Minimally Invasive Testing Technologies
- 3.3.3. Expansion into Rural and Underserved Areas

Chapter 4. Global EMEA Point-Of-Care Diagnostics Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global EMEA Point-Of-Care Diagnostics Market Size & Forecasts by Product 2022-2032

5.1. Segment Dashboard
5.2. Global EMEA Point-Of-Care Diagnostics Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 5.2.1. Glucose Testing
- 5.2.2. Cancer Marker
- 5.2.3. Coagulation Testing
- 5.2.4. Infectious Disease

Chapter 6. Global EMEA Point-Of-Care Diagnostics Market Size & Forecasts by End Use 2022-2032

6.1. Segment Dashboard
6.2. Global EMEA Point-Of-Care Diagnostics Market: End Use Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 6.2.1. Clinics
- 6.2.2. Home

Chapter 7. Global EMEA Point-Of-Care Diagnostics Market Size & Forecasts by Region 2022-2032

7.1. Europe Point-Of-Care Diagnostics Market
- 7.1.1. UK Point-Of-Care Diagnostics Market
  - 7.1.1.1. Product Breakdown Size & Forecasts, 2022-2032
  - 7.1.1.2. End Use Breakdown Size & Forecasts, 2022-2032
- 7.1.2. Germany Point-Of-Care Diagnostics Market
- 7.1.3. France Point-Of-Care Diagnostics Market
- 7.1.4. Spain Point-Of-Care Diagnostics Market
- 7.1.5. Italy Point-Of-Care Diagnostics Market
- 7.1.6. Rest of Europe Point-Of-Care Diagnostics Market
7.2. Middle East & Africa Point-Of-Care Diagnostics Market
- 7.2.1. Saudi Arabia Point-Of-Care Diagnostics Market
- 7.2.2. South Africa Point-Of-Care Diagnostics Market
- 7.2.3. Rest of Middle East & Africa Point-Of-Care Diagnostics Market

Chapter 8. Competitive Intelligence

8.1. Key Company SWOT Analysis
- 8.1.1. Abbott Laboratories
- 8.1.2. Siemens Healthineers AG
- 8.1.3. Roche Diagnostics
8.2. Top Market Strategies
8.3. Company Profiles
- 8.3.1. Abbott Laboratories
  - 8.3.1.1. Key Information
  - 8.3.1.2. Overview
  - 8.3.1.3. Financial (Subject to Data Availability)
  - 8.3.1.4. Product Summary
  - 8.3.1.5. Market Strategies
- 8.3.2. Siemens Healthineers AG
- 8.3.3. Roche Diagnostics
- 8.3.4. Danaher Corporation
- 8.3.5. QuidelOrtho Corporation
- 8.3.6. bioMerieux SA
- 8.3.7. Becton, Dickinson and Company
- 8.3.8. Sysmex Corporation
- 8.3.9. Hologic, Inc.
- 8.3.10. Thermo Fisher Scientific Inc.

Chapter 9. Research Process

9.1. Research Process
- 9.1.1. Data Mining
- 9.1.2. Analysis
- 9.1.3. Market Estimation
- 9.1.4. Validation
- 9.1.5. Publishing
9.2. Research Attributes